The future of precision medicine starts here
Our mission is to develop targeted microbiome-based therapeutics and molecular diagnostic tools to prevent and treat diseases of high unmet medical need
See Our Pipeline
Developing better therapies through a deep understanding of human microbial ecology
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing targeted live biotherapeutic products to prevent and treat diseases of high unmet medical need. By leveraging our proprietary Precision Symbiotics Platform™ and in-house GMP-manufacturing capabilities, we are rapidly expanding our product pipeline into new indications with multiple programs in preclinical and clinical-stage development.
Our Platform
Publications
Microbial Genomics
Finding the right fit: evaluation of short-read and long-read sequencing approaches to maximize the utility of clinical microbiome data
Read More
News
Siolta Therapeutics awarded NIH grant funding
Advance Technology Small Business Innovation Grant Award from NIAID
Read More
News
Siolta Collaboration with Bio-Me
Microbiome-based Prognostics for Early Identification of Allergy and Asthma
November 23, 2020
Read More